Kasai Portoenterostomy for Biliary Atresia
Treatment for Digestive Congenital Anomalies
Effectiveness
70%
Safety Score
40%
Clinical Trials
20
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Time to Effect
Bile flow improvement over 1-3 months
Treatment Duration
Acute (surgical), 1-3 weeks hospitalization, lifelong follow-up and potential transplant
Evidence Quality
MODERATEConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,000
Monitoring:$100,000
Side Effect Mgmt:$20,000
Total Annual:$121,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
55
Outcome-Based Costs
Cost per Responder
$172,857
Cost per Remission
$242,000
Kasai Portoenterostomy for Biliary Atresia Outcomes
for Digestive Congenital Anomalies
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+70%
Remission Rate
+50%
Common Side Effects
Cholangitis (bacterial infection of bile ducts)
+45%
Portal hypertension
+30%
Ascites
+15%
Failure to establish bile flow
+35%
Sources:
Active Clinical Trials
6 active trials recruiting for Kasai Portoenterostomy for Biliary Atresia in Digestive Congenital Anomalies
Umbilical Cord Mesenchymal Stem Cell Therapy for Biliary Atresia
NCT07797673RECRUITINGPHASE1
40 participants
INTERVENTIONAL
Jakarta Pusat, Indonesia
Started: Sep 1, 2026
Cholangitis Definition and Treatment After Kasai Hepatoportoenterostomy for Biliary Atresia: TRACK-BA Study (TRacking Cholangitis Post Kasai in Biliary Atresia)
NCT07129655NOT YET RECRUITING
40 participants
OBSERVATIONAL
Geneva, Switzerland
Started: Oct 1, 2025
Clinical Outcomes of Early Kasai Surgery With Umbilical Cord MSCs in Biliary Atresia
NCT07011199NOT YET RECRUITINGPHASE1
14 participants
INTERVENTIONAL
Semarang, Indonesia
Started: Jun 17, 2025
High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia
NCT05072626RECRUITING
300 participants
OBSERVATIONAL
Shanghai, China
Started: Oct 11, 2021
Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia
NCT06708572RECRUITINGNA
40 participants
INTERVENTIONAL
Cairo, Egypt
Started: Dec 1, 2024
Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy
NCT05925309RECRUITINGNA
356 participants
INTERVENTIONAL
Shanghai, China
Started: Jul 1, 2023
Completed Clinical Trials
9 completed trials for Kasai Portoenterostomy for Biliary Atresia in Digestive Congenital Anomalies
Kasai Portoenterostomy Timing and Outcomes in Biliary Atresia
NCT07328204COMPLETED
200 participants
OBSERVATIONAL
Hangzhou, China
Started: Dec 1, 2025
Outcome of Kasai Portoenterostomy in Biliary Atresia in Upper Egypt
NCT05925543COMPLETED
45 participants
OBSERVATIONAL
Aswān, Egypt
Started: Jan 1, 2019
Survival With Own Liver of Conventional Versus Laparoscopic Kasai for Biliary Atresia
NCT01063699COMPLETEDNA
56 participants
INTERVENTIONAL
Hanover, Germany
Started: Aug 1, 2003
N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy
NCT03499249COMPLETEDPHASE2
13 participants
INTERVENTIONAL
Houston, United States
Started: May 18, 2018
Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy
NCT04370145COMPLETEDPHASE4
160 participants
INTERVENTIONAL
Wuhan, China +1 more
Started: May 1, 2021
Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai
NCT04524390COMPLETEDPHASE2
75 participants
INTERVENTIONAL
Phoenix, United States +21 more
Started: Jul 8, 2021
Norepinephrine for Prevention of Intraoperative Hypotension in Infants Undergoing Kasai Portoenterostomy
NCT05521152COMPLETEDPHASE3
31 participants
INTERVENTIONAL
Cairo, Egypt
Started: Aug 28, 2022
Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia After the Kasai Portoenterostomy
NCT00166868COMPLETEDNA
30 participants
INTERVENTIONAL
Taipei, Taiwan
Started: Dec 1, 2003
Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)
NCT04336722COMPLETEDPHASE3
254 participants
INTERVENTIONAL
Los Angeles, United States +71 more
Started: Jul 8, 2020
Showing 20 of 22 total trials